Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS ...

Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.

CEO Mark Goldsmith highlighted significant advancements in the company's strategic priorities, particularly in the development of RAS(ON) inhibitors targeting RAS-addicted cancers. Progress was made ...

Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...

Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C-mutant non-small ...

We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Revolution Medicines, Inc. is one ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced ...

Putting patients on renin-angiotensin system (RAS) inhibiting drugs after transcatheter aortic-valve replacement (TAVR) may reverse some of their ventricular damage and cut long-term risks for atrial ...

– Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasibin KRAS-mutated colorectal cancer cells – – Data support ...